Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | TNKS | O95271 | 2/20 | 0.39 |
| ▸ | PARP1 | P09874 | 6/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.35 |
| ▸ | TTK | P33981 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23482394 | 0.79 | CYP2A6 (0.53) | CYP2A6HRH3PARP1DAOCA2 | |
| SCHEMBL5361224 | 0.73 | CYP2A6 (0.58) | CYP2A6DAOALDH1A1TSHRTAAR1 | |
| SCHEMBL29466343 | 0.73 | CYP2A6 (0.58) | CYP2A6DAOALDH1A1TSHRTAAR1 | |
| SCHEMBL28965281 | 0.73 | CYP2A6 (0.43) | CYP2A6DAO | |
| SCHEMBL29965121 | 0.72 | CYP2A6 (0.45) | CYP2A6DAOHDAC3HDAC6 | |
| SCHEMBL23458852 | 0.72 | CYP2A6 (0.45) | CYP2A6DAOHDAC3HDAC6 | |
| SCHEMBL23482386 | 0.72 | CYP2A6 (0.45) | CYP2A6DAO | |
| SCHEMBL4962752 | 0.71 | CYP2A6 (0.47) | CYP2A6ALDH1A1HDAC6 | |
| SCHEMBL2548885 | 0.69 | CYP2A6 (0.58) | CYP2A6DAOALDH1A1TSHR | |
| SCHEMBL286843 | 0.69 | CYP2A6 (0.58) | CYP2A6DAOALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101223143-A | 3-cyanoquinoline inhibitors of TPL2 kinase and methods of making and using the same | WYETH CORP (US) | 2008-07-16 | — | — | CN | disclosed |
| EP-1888529-A2 | 3-CYANOQUINOLINE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME | Wyeth (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20060264460-A1 | 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2006-11-23 | — | — | US | disclosed |
| WO-2006124692-A2 | 3-CYANOQUINOLINE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264460-A1 | 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same | TNNI3K, CSNK1A1L, CDKL1 | CYP2A6 3514/4885HRH3 669/4885TNKS 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.